Table 1 Baseline characteristics according to primary tumor location
Characteristics | Right colon (n = 23) | Left colon and rectum (n = 147) | P-value* |
|---|---|---|---|
Age (years) | 0.546 | ||
Median (range) | 57 (36–72) | 55 (24–74) | |
Gender | 0.154 | ||
Female | 10 (43.5%) | 42 (28.6%) | |
Male | 13 (56.5%) | 105 (71.4%) | |
Stage at presentation | 0.292 | ||
Stage IV | 20 (87.0%) | 110 (74.8%) | |
Stage I-III | 3 (13.0%) | 37 (25.2%) | |
Histology | 0.031 | ||
W/D or M/D | 16 (80.0%) | 136 (95.0%) | |
P/D or SRCC | 4 (20.0%) | 7 (5.0%) | |
Number of metastasized organs | >0.999 | ||
1 | 13 (56.5%) | 81 (55.1%) | |
≥ 2 | 10 (43.5%) | 66 (44.9%) | |
Metastasized organ | |||
Liver | 12 (52.2%) | 106 (72.1%) | 0.086 |
Lung | 7 (30.4%) | 65 (44.2%) | 0.260 |
Peritoneum | 6 (26.1%) | 13 (8.8%) | 0.026 |
Treatment lines | 0.921 | ||
3 | 16 (69.6%) | 104 (70.7%) | |
4 | 6 (26.1%) | 35 (23.8%) | |
≥5 | 1 (4.3%) | 8 (5.4%) | |
Prior treatment | |||
Oxaliplatin | 23 (100%) | 144 (98.0%) | 1.00 |
Bevacizumab | 7 (30.4%) | 25 (17.0%) | 0.151 |
5-fluoropyrimidine | 20 (87.0%) | 136 (92.5%) | 0.408 |
Regimen | 0.482 | ||
Cetuximab + irinotecan | 13 (56.5%) | 97 (66.0%) | |
Cetuximab monotherapy | 10 (43.5%) | 50 (34.0%) | |
BRAF | <0.001 | ||
Wild-type | 14 (60.9%) | 139 (94.6%) | |
Mutant | 9 (39.1%) | 8 (5.4%) | |
PIK3CA | 0.018 | ||
Wild-type | 20 (87.0%) | 145 (98.6%) | |
Mutant | 3 (13.0%) | 2 (1.4%) | |
MSI status | 0.156 | ||
MSS | 19 (82.6%) | 85 (57.8%) | |
MSI-low | 0 (0%) | 3 (2.0%) | |
MSI-high | 0 (0%) | 1 (0.7%) | |
Not checked | 4 (17.4%) | 58 (39.5%) | |